Guide
The approved pills changed the maths
Two oral GLP-1s were approved either side of the new year, both starting at $149 a month. That undercuts a large part of the compounded market.
Updated 2026-09-18 · Prices verified independently
For two years the answer to 'why compounded?' was simply price. Two approved pills arrived either side of this new year and largely took that answer away.
Both start at $149 a month self-pay. That is more than the cheapest compounded programmes — SuperHealthy Rx is $85 and Trimi is $125 — but it is less than the majority of what we track, and it buys a product the FDA has actually reviewed.
What changed, in one line
An FDA-approved medication now starts at roughly the same monthly figure as a mid-priced compounded injection. If you were paying a premium for compounded because it was the only affordable option, that premise expired in 2026 and a lot of sites have not noticed.
Wegovy pill (oral semaglutide)
Approved late December 2025, launched in the US on 5 January 2026. The first oral GLP-1 approved for weight management — the same active ingredient as the Wegovy injection, taken as a daily tablet.
Self-pay from $149/month for the 1.5 mg starting dose. The 4 mg dose was offered at $149/month through 15 April 2026 and $199/month after, with the highest doses around $299/month.
Available through LillyDirect-style manufacturer channels and telehealth partners including Ro, GoodRx Care Direct and Walgreens.
Foundayo (orforglipron)
FDA approved 1 April 2026. The first oral small-molecule, non-peptide GLP-1 receptor agonist approved for weight management. Unlike oral semaglutide it is not a peptide, so it has no food-and-water timing restrictions of the same kind.
Self-pay from $149/month for the lowest 0.8 mg dose, about $199/month at 2.5 mg, and roughly $299-$349/month at higher doses.
Self-pay through LillyDirect, with telehealth partners including Ro.
Who should actually consider switching
- Anyone paying more than about $200 a month for a compounded injection. You are now paying a premium for a non-approved product, which is a strange place to be.
- Anyone who never wanted to inject. This is the obvious one — a genuine approved alternative now exists at a sane price.
- Anyone uneasy about the compounding rules. The 2026 regulatory direction is not friendly to compounded GLP-1s; see is compounded still legal.
- Medicare beneficiaries. From July 2026 you may be able to get an approved GLP-1 for $50 a month — see the Medicare programme.
Who probably should not
If you are already on Trimi or SuperHealthy Rx at under $130 a month, tolerating it well and getting results, the approved pills cost more. That is a real reason to stay put. The comparison changes if your programme raises prices or your dose pushes you into a higher tier.
Whichever direction you are considering, it is a conversation with a prescriber rather than a purchase decision. Both drugs have contraindications, and switching between them is not simply swapping one box for another.
Read next
- Medicare, GLP-1s and the $50 month
CMS is running a time-limited programme giving eligible Part D members certain GLP-1s for $50 a month. If you are on Medicare, read this before paying cash for anything.
- What you actually pay
Six pricing tricks that turn a $99 advert into a $298 statement, and how to check before you hand over a card.
- Is compounded GLP-1 medication still legal?
Short answer: yes, but in a much narrower form than in 2024 — and the FDA moved again this year.
- Tirzepatide vs semaglutide
One trial put them head to head. The result was not close — but the cheaper drug still wins for some people.
- The cheapest GLP-1 programmes, ranked honestly
Every provider ordered by what you pay in month two, with membership fees included and teaser rates thrown out.
Coreage Rx pays us a commission on sign-ups through our links. It does not affect our scores or rankings. How we rate · Disclosure